US 12,070,467 B2
Method of treating ciliated tissue using CSA micelles
Carl Genberg, Las Vegas, NV (US); and Paul B. Savage, Mapleton, UT (US)
Assigned to Brigham Young University, Provo, UT (US)
Appl. No. 16/979,487
Filed by Carl Genberg, Las Vegas, NV (US); and Paul B. Savage, Mapleton, UT (US)
PCT Filed Mar. 7, 2019, PCT No. PCT/US2019/021232
§ 371(c)(1), (2) Date Sep. 9, 2020,
PCT Pub. No. WO2019/173642, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/640,010, filed on Mar. 7, 2018.
Prior Publication US 2021/0361672 A1, Nov. 25, 2021
Int. Cl. A61K 31/56 (2006.01); A61K 47/10 (2017.01)
CPC A61K 31/56 (2013.01) [A61K 47/10 (2013.01)] 20 Claims
 
1. A method of therapeutically or prophylactically treating a microbial infection of ciliated tissue of a subject in need thereof, the method comprising:
providing a treatment composition including:
a cationic steroidal antimicrobial (CSA) compound comprising CSA molecules,
a poloxamer, and
a carrier,
wherein the poloxamer is included in an amount and combined with the CSA compound in a manner so that the CSA compound is encapsulated in and stabilized by micelles formed by the poloxamer so as to decrease cytotoxicity of the CSA compound to ciliated tissue,
wherein the poloxamer is included in the treatment composition in an amount, by weight, that is about 100 to 1000 times the amount of the CSA compound, by weight,
wherein at least 75% of the CSA molecules are individually sequestered CSA molecules or particles less than 1 μm in size; and
administering the treatment composition to the ciliated tissue of the subject in need thereof;
wherein the treatment composition therapeutically or prophylactically treats the microbial infection by killing or deactivating microbes associated with the ciliated tissue without disrupting ciliary function.